Trial Profile

A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Motolimod (Primary) ; Nivolumab (Primary)
Indications Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
Focus Biomarker; Pharmacodynamics
Sponsors Celgene Corporation; VentiRx Pharmaceuticals

Most Recent Events

23 Oct 2019 Status changed from recruiting to discontinued.
23 Oct 2017 Results (n=14) assessing the effect of neoadjuvant cetuximab plus motolimod, published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
06 Jan 2016 New drug 'Nivolumab' has been added in the study and also 1 treatment arm has been added as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com